跳至主要内容
临床试验/NCT02623673
NCT02623673已完成不适用

Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema

Retina Clinic, Sao Paulo, Brazil1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2015年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
20
试验地点
1
主要终点
Improvement in BCVA

研究概览

简要总结

Retrospective cases series is a non-randomized, open-label, single-center investigation (Retina Clinic, São Paulo, Brazil) of patients diagnosed with macular edema secondary to diabetic retinopathy (DME) and retinal vein occlusions who underwent to simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and implant of dexamethasone 0.7mg.

详细描述

This retrospective cases series is a non-randomized, open-label, single-center investigation (Retina Clinic, São Paulo, Brazil) approved by the Institutional Review Board of Hospital Oftalmológico de Sorocaba/SP, and adhered to the tenets of the Declaration of Helsinki. Were included patients older than 18 years, treated between April 2014 and July 2015, diagnosed with macular edema secondary to diabetic retinopathy (DME) and retinal vein occlusions who underwent to simultaneous treatment with intravitreal injection of bevacizumab 1.25mg (Avastin; Genentech, South San Francisco, CA) and intravitreal implant of dexamethasone 0.7mg (Ozurdex; Allergan, Inc, Irvine, CA).

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • central macular thickness > 300 µm on optical coherence tomography (OCT)
  • macular edema secondary to diabetic retinopathy (DME) and retinal vein occlusions

排除标准

  • intravitreal anti-VEGF within 6 weeks
  • treatment with laser or intravitreal corticosteroids within 3 months of study entry.

研究组 & 干预措施

bevacizumab plus dexamethasone 0.7mg

simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg

干预措施: simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg. (Drug)

结局指标

主要结局

Improvement in BCVA

时间窗: 6 months

次要结局

未报告次要终点

研究者

发起方
Retina Clinic, Sao Paulo, Brazil
申办方类型
Other
责任方
Principal Investigator
主要研究者

Gabriel Costa de Andrade

Gabriel Costa de Andrade

Retina Clinic, Sao Paulo, Brazil

研究点 (1)

Loading locations...

相似试验